This innovation shows an approach for diagnosing and classifying gliomas, a type of brain tumor, using autoantibody profiling. By analyzing the immune response to specific proteins, the researchers developed a panel of classifiers capable of accurately distinguishing between healthy individuals and glioma patients, as well as differentiating between various grades and subtypes of gliomas. These classifiers offer the potential for early detection and minimally invasive diagnosis, leading to improved treatment decisions and better outcomes for patients. Additionally, pathway analysis revealed insights into the underlying mechanisms of glioma development, paving the way for targeted therapies in the future.
Figure (1) Experimental workflow and data preprocessing illustrates the experimental procedure involved in the microarray experiments in this study; (2) Experimental workflow and data preprocessing represents the quality of the proteins spotted on the microarray. The zoomed-in panel shows the increase in signal intensity with increase in concentration of purified GST protein spotted
Current diagnostic methods for gliomas, a type of brain tumor, often rely on invasive procedures like biopsies, leading to patient discomfort and potential risks. Additionally, existing imaging techniques may not accurately distinguish between tumor grades and subtypes, complicating treatment decisions. Moreover, the inability to detect gliomas at early stages limits the effectiveness of interventions.
- Novel Biomarker Panel: The proposed panel of protein autoantibody biomarkers introduces a new strategy for glioma diagnosis with high accuracy and specificity.
- Comprehensive Biomarker Selection: Incorporates a diverse set of biomarkers such as SNX1, IGHG1, EYA1, CD44, NEDD9, and others to effectively distinguish between different glioma grades and subtypes.
- High Diagnostic Performance: Demonstrates remarkable sensitivity and specificity, significantly improving diagnostic reliability compared to conventional methods.
- Minimally Invasive Testing: Offers a less invasive alternative to current diagnostic techniques, enhancing patient comfort and clinical applicability.
- Clinical Compatibility: Utilizes ELISA-based assays, enabling straightforward integration into routine clinical laboratory workflows.
- Improved Patient Management: Facilitates early detection and accurate classification of gliomas, supporting timely and tailored treatment decisions for better patient outcomes.
Diagnostic Device: The prototype diagnostic device integrates microfluidic channels, biosensors, and a compact optical detection system. It utilizes standard electrical power (5V DC) and may require specific chemical reagents for sample processing. The dimensions are approximately 15cm x 10cm x 5cm, making it portable and suitable for field deployment. The device can process multiple samples concurrently, with a throughput of up to 50 samples per hour. Performance metrics include accuracy (>95%), sensitivity (>90%), and specificity (>95%) in classifying individuals as healthy controls, falciparum malaria, or vivax malaria based on protein expression patterns.
The technology is currently in the laboratory validation stage. It has been successfully tested using a panel of serum samples from glioma patients (Grades II, III, IV including SVZp and SVZn subtypes) and healthy individuals using human proteome microarrays. Classifier proteins with high sensitivity and specificity have been identified for each grade and subtype. However, the assay is not yet commercially deployed and awaits further clinical validation, assay standardization (e.g., ELISA or microfluidic kits), and regulatory approvals for clinical use.
4
The invention contributes to improved patient outcomes by enabling early detection and accurate classification of diseases, which in turn leads to more effective treatment strategies and higher survival rates. It helps reduce the overall healthcare burden by minimizing the need for intensive late-stage treatments and prolonged hospitalizations. Early diagnosis also enhances patients' quality of life by allowing timely intervention that can preserve cognitive function and overall well-being. Additionally, the technology supports significant cost savings by reducing expenses associated with managing advanced stages of disease, making healthcare delivery more efficient and sustainable.
- Clinical Diagnostics: These biomarkers could revolutionize the diagnosis of gliomas, enabling earlier detection and more accurate classification of tumor grades.
- Personalized Medicine: By identifying specific biomarker profiles associated with different grades and subtypes of gliomas, treatment strategies can be tailored to individual patients.
- Cancer Research: These findings contribute to our understanding of glioma biology, potentially uncovering new therapeutic targets and pathways for drug development.
- Medical Imaging: Biomarker-based assays could complement existing imaging techniques, providing clinicians with a more comprehensive picture of tumor progression and response to treatment.
- Drug Development: Pharmaceutical companies may use these biomarkers to screen potential drug candidates and monitor treatment efficacy in clinical trials.
Geography of IP
Type of IP
3028/MUM/2015
469972